NAPSRx News: Bayer aims to expand Life Science businesses

WASHINGTON - March 13, 2015 - PRLog -- Bayer looks to increase sales in their Life Science division by an annual 6 percent until 2017 which is primarily based on the success of their pharmaceuticals division. Blockbuster blood thinner Xarelto gained a 32 percent share in the anticoagulant market, ahead of Boehringer's Pradaxa and Bristol-Myers Squibb's Eliquis, according to the company. CEO Dr. Marijn Dekkers stated,  “The outlook for our health care business is particularly positive thanks to the five pharmaceutical products we recently launched. They have played a crucial role in making us one of the fastest-growing large companies in the pharmaceutical industry.”  Sales of Xarelto, eye medicine Eylea, and cancer drugs Stivarga™ and Xofigo™ along with pulmonary hypertension drug Adempas™ are projected to increase toward EUR 4 billion in 2015 (2014: EUR 2.9 billion) which will put peak sales of these products combined at an estimated total of at least EUR 7.5 billion according to Dekkers.

Bayer’s strategy is to invest in the research and development of projects in progress further establishing a diversified pharmaceutical pipeline. Bayer expects the mid- and late-stage projects in its pipeline to make significant progress over the next 12 to 18 months. ““We want to help improve treatment options for patients in our research areas of cardiology, hematology, oncology and gynecology,” said Dekkers. The company plans to spend more than EUR 4.0 billion (2014: EUR 3.6 billion) on research and development in 2015 alone and more than half of that amount which amounts to approximately EUR 2.2 billion will be reserved for the Pharmaceuticals business .

CANDIDATES WHO WANT TO BREAK INTO A PHARMACEUTICAL SALES CAREER!

Now is the time to enter this wonderful field! As Bayer continues to make strides toward a more profitable future for their pharmaceuticals division, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to market their product both proficiently and efficiently.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/